Evidence map›Paper›PMID 35669120›Full record

ArticleFrontiers in cellular and infection microbiology2022

Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures.

Bruna Raphaela Oliveira Silva, Wellington Francisco Rodrigues, Daniela Gomes Pires Abadia, Djalma A Alves da Silva, Leonardo E Andrade E Silva, Chamberttan S Desidério, Thais Soares Farnesi-de-Assunção, Juliana C Costa-Madeira, Rafaela M Barbosa, Anna V Bernardes E Borges and 18 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Bruna Raphaela Oliveira SilvaDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Wellington Francisco RodriguesDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Daniela Gomes Pires AbadiaDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Djalma A Alves da SilvaDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Leonardo E Andrade E SilvaDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Chamberttan S DesidérioDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Thais Soares Farnesi-de-AssunçãoDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Juliana C Costa-MadeiraDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Rafaela M BarbosaDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Anna V Bernardes E BorgesDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Andrezza C C Hortolani CunhaPostgraduate Program in Physiological Sciences, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Loren Q PereiraLaboratory of Hematological Research of the Federal University of Triângulo Mineiro and Regional Blood Center of Uberaba - Hemominas Foundation, Uberaba, Brazil.
Fernanda R HelmoDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Marcela Rezende LemesDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Laís M BarbosaDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Rafael O TrevisanDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Malu Mateus Santos ObataDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Giovanna F BuenoDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Fabiano V MundimDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Ana Carolina M Oliveira-ScusselDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Ivan B MonteiroUNIMED São Domingos Hospital, Uberaba, MG, Brazil. José Alencar Gomes da Silva Regional Hospital, Uberaba, Brazil.
Yulsef M FerreiraJosé Alencar Gomes da Silva Regional Hospital, Uberaba, Brazil.
Guilherme H MachadoMário Palmério University Hospital, Uberaba, Brazil.
Kennio Ferreira-PaimDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Hélio Moraes-SouzaLaboratory of Hematological Research of the Federal University of Triângulo Mineiro and Regional Blood Center of Uberaba - Hemominas Foundation, Uberaba, Brazil.
Marcos Vinicius da SilvaDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Virmondes Rodrigues JúniorDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.
Carlo José Freire OliveiraDepartment of Immunology, Microbiology and Parasitology, Federal University of Triângulo Mineiro, Uberaba, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, also known as coronavirus disease 2019, is an infectious viral disease caused by SARS-CoV-2, a novel coronavirus. Since its emergence, its epidemiology has been explored; however, for some regions of the world, COVID-19's behavior, incidence, and impact remain unclear. In continental nations like Brazil, this lack of knowledge results in nonuniform control, prevention, and treatment measures, which can be controversial in some locations. This study aimed to describe the epidemiological profile of patients with COVID-19 in the macroregion of Triângulo Sul in the state of Minas Gerais (MG), Brazil. Between March 25 and October 21, 2020, data were collected and statistically analyzed from 395 hospitalized patients in the city of Uberaba, MG, suspected to have moderate or severe forms of the disease. Of the 395 suspected cases, 82% were confirmed to be positive for COVID-19. The mean age of positive patients was 58.4 years, and 60.76% were male. Following these patients throughout their hospitalization, a mortality rate of 31.3% was observed. In the population positive for COVID-19, the risk of death increased by 4% for each year of the patient's age. Likewise, the older the patient, the longer their hospitalization and the higher the risk of developing acute respiratory failure. Among the treatments tested in patients, heparin was associated with protection against mortality, and the absence of anticoagulant use was linked to a more than six times greater risk of death. Finally, comorbidities in patients with COVID-19 were positively correlated with increased hospitalization time. In summary, this study revealed that age, presence of comorbidities, length of hospitalization, and drug treatment considerably altered COVID-19's lethality. To understand infection rates and the factors involved in COVID-19's lethality, knowledge of the local epidemiology is necessary.

Indexed as

COVID-19BrazilFemaleHospitalizationHumansInpatientsMaleMiddle AgedSARS-CoV-2BrazilCOVID-19epidemiologyinpatientstreatment

Identifiers

PMID35669120
PMCPMC9164138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.